Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Depreciation & Amortization (CF) (2016 - 2026)

Heron Therapeutics filings provide 15 years of Depreciation & Amortization (CF) readings, the most recent being $529000.0 for Q1 2026.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 3.99% to $529000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $2.3 million, a 2.63% decrease, with the full-year FY2025 number at $2.3 million, down 7.14% from a year prior.
  • Depreciation & Amortization (CF) hit $529000.0 in Q1 2026 for Heron Therapeutics, down from $537000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $791000.0 in Q4 2022 to a low of $529000.0 in Q1 2026.
  • Median Depreciation & Amortization (CF) over the past 5 years was $671000.0 (2022), compared with a mean of $654352.9.
  • Biggest five-year swings in Depreciation & Amortization (CF): grew 10.13% in 2023 and later dropped 20.08% in 2024.
  • Heron Therapeutics' Depreciation & Amortization (CF) stood at $791000.0 in 2022, then dropped by 9.48% to $716000.0 in 2023, then decreased by 18.85% to $581000.0 in 2024, then decreased by 7.57% to $537000.0 in 2025, then decreased by 1.49% to $529000.0 in 2026.
  • The last three reported values for Depreciation & Amortization (CF) were $529000.0 (Q1 2026), $537000.0 (Q4 2025), and $615000.0 (Q3 2025) per Business Quant data.